Colorado company developing potential prescription psilocybin product

Dr. David Kroll, PhD, says right now psilocybin is listed as a schedule one drug with no medical benefit and a high potential for abuse. “So, it is a risky proposition for these companies," he said, "but the clinical trials that have come out to date have been so promising that these companies have been able to acquire investors."